StreetAlpha.app
Home › Stocks › GRCE

Grace Therapeutics, Inc. (GRCE)

$1.71
▼ −1.16%
LAST CLOSE · NOV 20

Grace Therapeutics develops reformulated medicines for rare diseases, led by an injectable form of nimodipine for patients with brain bleeding. It last closed at $1.71 on Nov 20, down 1.16% on the day. The next earnings report for GRCE is expected around Thu, Feb 11, 2027. For the quarter ended Sep 2026, GRCE reported EPS of -$0.11. Over its last 8 reports the stock moved an average of 2.6% the session after earnings. Over the last 12 months GRCE insiders bought $891K of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is GRCE in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold GRCE.

Key Stats

Last 12 months
Results
Net income
−$21.4M
EPS (diluted)
−$1.16
Valuation
Market cap
$36.0M
21.0M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$21.3M
At Sep 30
Shareholder equity
$55.5M
Shares outstanding
21.0M
At Nov 11
Fiscal year endsMarch
ExchangeNasdaq
Financials history
FY2022: −$9.8M−$9.8MFY2022FY2023: −$42.4M−$42.4MFY2023FY2024: −$12.9M−$12.9MFY2024FY2025: −$9.6M−$9.6MFY2025FY2026: −$7.8M−$7.8MFY2026

From GRCE's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
Feb 11
Estimated date · Time not announced
Reported EPS
-$0.11
Quarter ended Sep 2026
Year ago EPS
-$0.06
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.36Dec '24Mar 2025: $0.10Mar '25Jun 2025: -$0.21Jun '25Sep 2025: -$0.06Sep '25Dec 2025: -$0.14Dec '25Mar 2026: -$0.06Mar '26Jun 2026: -$0.91Jun '26Sep 2026: -$0.11Sep '26Latest -$0.11
Revenue by quarter
Not enough quarters on file yet.
How GRCE moved after its last 8 reports
Average move the session after a report ±2.6%
Nov 12, 2026Time not announced−2.4%
Aug 13, 2026Time not announced−1.4%
Jun 18, 2026Time not announced+7.2%
Feb 12, 2026Time not announced−1.7%
Nov 13, 2025Time not announced+2.3%
Aug 12, 2025Time not announced+3.4%
Jun 23, 2025Time not announced−2.3%
Feb 13, 2025Time not announced+0.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on GRCEStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Technical Analysis

GRCE · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 7% below its 20 day and 15% below its 50 day average. It is 57% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 35), near oversold. The nearest support is the swing low (Nov 3) at $1.70, and the nearest resistance the Pivot at $1.74.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 6.6%/day
Key levels
$5.1852 week high+202.9%
$2.68200 day average+56.7%
$2.10100 day average+22.8%
$2.05Swing high (Oct 29)+19.9%
$1.9750 day average+15.2%
$1.8220 day average+6.4%
$1.79Pivot R1+4.7%
$1.74Pivot+1.8%
$1.71Last close
$1.70Swing low (Nov 3)−0.6%
$1.65Pivot S1−3.5%
$1.6452 week low−4.1%
Indicators
RSI (14)34.71Weak, oversold below 30Neutral
MACD-0.07Below its signal lineBearish
Stochastic22.5Middle of its rangeNeutral
ADX (14)31.4Trending down
Williams %R-81.1Oversold below −80, overbought above −20Oversold
CCI (20)-120.2Oversold below −100, overbought above 100Oversold
Rate of change−7.6%Change over 10 sessionsBearish
ATR (14)$0.11Typical daily range, 6.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for GRCE

What happened before

See how GRCE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for GRCEHow many large options trades hit GRCE, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

GRCE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ●18 buying vs 18 selling
  • ▲Held by funds +17.3 pts
  • ▲Funds holding +5
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding3833+15.2%
In funds' top 1000–
Held by funds36.1%18.8%+17.3 pts
New / increased12 / 610 / 12−18.2%
Reduced / sold out10 / 83 / 11+28.6%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See GRCE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

GRCE Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$891K12 buys · 2 insiders
Sold$00 sales · 0 insiders
Cluster buy: 2 insiders bought $270K between Aug 14 and Sep 9.
2026-08 bought $24K2026-09 bought $294K2026-10 bought $456K2026-11 bought $116KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 18Opaleye Management Inc.10% ownerBuy48,060$1.74$83K
Nov 5Opaleye Management Inc.10% ownerBuy18,442$1.79$33K
Oct 26Opaleye Management Inc.10% ownerBuy87,801$1.81$159K
Oct 19Opaleye Management Inc.10% ownerBuy4,256$1.88$8K
Oct 16Opaleye Management Inc.10% ownerBuy71,065$1.92$136K
Oct 12Opaleye Management Inc.10% ownerBuy14,632$2.03$30K
Every insider buy and sale for GRCE over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See GRCE insider trades →

From SEC Form 4 filings by GRCE's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GRCE is in one of them and how their past GRCE trades turned out.

GRCE in the AI portfolios
Loading…

GRCE News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered GRCE in an article yet. Here's the latest on the wider market.

GRCE in the news

About Grace Therapeutics

Grace Therapeutics is a pharmaceutical company based in Princeton, New Jersey, that develops reformulated versions of existing medicines for rare and orphan diseases. Its lead candidate, GTx-104, is an injectable form of nimodipine designed for intravenous delivery to patients with aneurysmal subarachnoid hemorrhage, a type of stroke. Its target customers include hospitals, physicians and patients. Its product candidates are still in development and have not yet been approved for sale.

Headquarters
Princeton, NJ